Search

Your search keyword '"Valim, Valéria"' showing total 225 results

Search Constraints

Start Over You searched for: Author "Valim, Valéria" Remove constraint Author: "Valim, Valéria" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
225 results on '"Valim, Valéria"'

Search Results

1. Brazilian version of the “Primary Sjögren’s Syndrome - Quality of Life questionnaire (PSS-QoL)”: translation, cross-cultural adaptation and validation

3. Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases

4. Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose

5. Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients

6. Brazilian version of the “Primary Sjögren’s Syndrome - Quality of Life questionnaire (PSS-QoL)”: translation, cross-cultural adaptation and validation

7. Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study.

8. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination

9. Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2

11. EVENTOS ADVERSOS À 3ª DOSE DAS VACINAS ASTRAZENECA E PFIZER EM UMA COORTE DE TRABALHADORES DA SAÚDE

12. Correction to: V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells

13. The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis.

14. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil)

15. Quality of life in spondyloarthritis: analysis of a large Brazilian cohort

16. V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells

17. Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study

18. Clinical risk factors for predicting anti-Sars-CoV-2 antibody immunoreactivity duration after mild COVID-19 infection

19. Recommendations for the treatment of Sjögren's syndrome

23. Evaluation of performance of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) in a Brazilian cohort of 1492 patients with spondyloarthritis: data from the Brazilian Registry of Spondyloarthritides (RBE)

24. CARDIOVASCULAR RISK IN SJÖGREN S DISEASE FROM THE BRAZILIAN SJÖGREN S DISEASE REGISTRY (REBRAS)

27. POSITIVITY OF ANTI-LA/SSB ANTIBODIES IN SJÖGREN S DISEASE IS ASSOCIATED WITH EXTRA-GLANDULAR SYSTEMIC MANIFESTATION: RESULTS FROM THE THE BRAZILIAN SJÖGREN S DISEASE REGISTRY (REBRAS)

28. THE EFFECT OF ANTIMALARIALS ON THE RISK AND SEVERITY OF BACTERIAL, VIRAL, FUNGAL AND SYSTEMIC SPECIFIC INFECTIONS IN RHEUMATOID ARTHRITIS

30. EFFECTS OF MANUAL VAGUS NERVE THERAPY COMBINED WITH TRANSCRANIAL DIRECT CURRENT STIMULATION ON PAIN IN WOMEN WITH FIBROMYALGIA: A RANDOMIZED CONTROLLED TRIAL

32. Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients

33. Comparison Of The Immunogenicity Among Covid-19 Vaccines Chadox1, Coronavac Or Bnt162b2 In Systemic Lupus Erythematosus (Sle): A Prospective Cohort

34. ARTICULAR SYSTEMIC DISEASE ACTIVITY AT DIAGNOSIS IS ASSOCIATED WITH DAMAGE, FATIGUE, PAIN AND DRYNESS OVER TIME IN PRIMARY SJÖGREN’S SYNDROME

35. SAFETY OF THE CORONAVAC AND CHADOX 1 COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM SAFER STUDY

36. FATIGUE IS ASSOCIATED WITH SYMPTOMS, DEPRESSION, ANXIETY, SLEEPINESS AND DISEASE ACTIVITY IN PRIMARY SJÖGREN’S SYNDROME

37. Safety assessment of BNT162b2, SinoVac and ChAdOx1 vaccines in Systemic Lupus Erythematosus patients – Data from SAFER Study

38. DIFFICULT ACCESS TO PREVENTION AND DETECTION MEASURES OF COVID-19 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

39. VALIDITY AND RELIABILITY OF THE BRAZILIAN VERSION OF THE PRIMARY SJÖGREN’S SYNDROME QUESTIONNAIRE

40. IMMUNOGENICITY AND SAFETY OF THE CHADOX-1 COVID-19 VACCINE IN PATIENTS WITH AUTOIMMUNE DISEASES AND HEALTHY CONTROLS: DATA FROM SAFER STUDY

42. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL

43. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis

44. REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)

45. EVENTOS ADVERSOS ÀS VACINAS CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES DA SAÚDE

46. REATIVIDADE VACINAL E DURAÇÃO DE RESPOSTA IMUNE DA CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES

47. EFETIVIDADE, IMUNOGENICIDADE E SEGURANÇA DA MEIA DOSE DA VACINA CHADOX1 NCOV-19 CONTRA SARS-COV2 (PROJETO VIANA)

49. Safety of the Methotrexate–leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil)

50. Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence

Catalog

Books, media, physical & digital resources